CLOs on the Move

Hotel Dieu Hospital

www.hoteldieu.com

 
Ambulatory care at Hotel Dieu Hospital (HDH) is specialized care that may include a scheduled visit to one or more hospital clinics, diagnostic or procedural areas. In some cases, a single health care professional, for example a surgeon or internal medicine physician, may see patients in a traditional clinic setting. Increasingly, patients and families will receive care in a team-based inter-disciplinary and/or inter-professional program, such as our pre-surgical screening, diabetes, breast assessment, bariatric, chronic pain or cardiac rehabilitation programs. Ambulatory care at HDH includes care for patients with urgent and less critical emergency problems at our Urgent Care Centre.    Hotel Dieu ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Bioject

Bioject Medical Technologies Inc. is a leader in the development of needle-free injection therapies with over 25 years of experience improving the administration of liquid medications; pharmaceuticals, vaccines, and biologics. Bioject's technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. This creates an ultra-fine stream of fluid that penetrates the skin, delivering medication in a fraction of a second. Bioject's systems are designed to deliver injected medications comfortably, accurately, and quickly - without the use of a needle. Bioject was founded in 1985 to develop needle-free injection systems to improve the comfort and safety of routine injections. From its early work focused on improving the characteristics of these delivery systems, the Company has created a broad technology platform for delivering a wide range of medications and vaccines to the subcutaneous, intramuscular and intradermal depths. Bioject has developed a portfolio of injection systems based on its core technology, the foundation for which is more than 80 issued and pending patents and an extensive body of technical know-how. These include durable devices designed for heavy use in a professional healthcare environment, and small, lightweight injectors designed for home use. With partners, Bioject is also developing inexpensive, pre-filled, disposable injection systems. Further validating its technology, Bioject and its partners have the largest volume of published studies using needle-free injection technology systems. Bioject's strategy is to form strategic partnerships with pharmaceutical, biotechnology, and animal health companies. The result is mutually beneficial agreements with these partners to develop customized injection systems to enhance the delivery of their injected medication or vaccine. Bioject has alliances with leading pharmaceutical, biotechnology, and animal health companies. Bioject's products are also used in public health, Physicians offices, and in cutting edge biomedical research at leading institutions around the globe.  

IMED Group

IMED Group is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Victor Medical

Victor Medical is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

MedVantX

MedVantX is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrity Applications

Integrity Applications is dedicated to developing breakthrough innovations in non-invasive glucose monitoring devices. Since its founding in 2001, Integrity Applications has been committed to improving the quality of life for people with diabetes by removing the obstacles of traditional invasive devices, namely painful pricking of fingertips, added costs as a result of disposables, as well as inconvenience. Integrity Applications has developed a state-of-the-art way to measure glucose levels using three non-invasive technologies, ultrasound, thermal, and electromagnetic in combination with a proprietary algorithm to produce a weighted glucose measurement. After proof of concept in 2002, Integrity Applications developed the first working prototype, GlucoTrack in August 2003. GlucoTrack® Model DF-F received CE Mark approval in June 2013 and KFDA in March 2016. GlucoTrack is currently being marketed in the European Union and in South Korea.